CyPath Lung Sales Soar 99% in 2025, Driving Record Revenue for bioAffinity Technologies
BIAF sits 65% above its 52-week low of $0.693.
Summary
bioAffinity Technologies announced record 2025 revenue and unit sales for its flagship lung cancer diagnostic, CyPath® Lung. Revenue from CyPath® Lung increased 87% year-over-year, with the number of tests performed rising 99%. This growth occurred despite a 34% decrease in total consolidated revenue, as the company strategically discontinued unprofitable pathology services to focus resources on CyPath® Lung's commercialization. This positive commercial update on their core product provides a crucial counterpoint to the recent news of a proposed reverse stock split to maintain Nasdaq listing. The strong performance of CyPath® Lung, alongside the recently initiated large-scale clinical study, indicates progress in both commercialization and product development. Investors will be watching for continued sales acceleration and the results of the clinical study, as well as the outcome of the reverse stock split.
At the time of this announcement, BIAF was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.69 to $46.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.